Our approach was to build a simulation model, looking to include all relevant considerations to estimate patient health outcomes and cost consequences for different HCC screening strategies for CHB patients in China: US, AFP, PIVKA-II, AFP+US, AFP+PIVKA-II, GAAD and GAAD+US. The gene discussed is AFP; the disease is hepatocellular carcinoma.